Open Access (No Firewall)
Link to this page: http://ipaknowledge.org/ipak-vaxxed-v-unvaxxed-study.php
We are now moving on to Phase 2 of our study, in which they will focus on the comparison of health outcomes associated with live vs. non-live vaccines, aluminum-containing vaccines vs. non-aluminum containing vaccines, as well as studying the impact of individual vaccines on specific health outcome risks. Become an IPAK Science Hero and make the world a safer place for our children through objective science.
In this study of over 3300 patients, we found ZERO ADHD in the unvaccinated group (N=561). We found that using billed office visits was a more powerful test than the weaker odds ratio of incidence. Even after blocking for healthcare exposure/age, family history of autoimmunity, and gender, the associations of many bad health outcomes were robust. Anemia was especially prominent in the vaccinated. Here is our announcement.
The IPAK team and Dr. Paul Thomas have published the first results from the Vaxxed vs. Unvaxxed study in the study "Relative Incidence of Office Visits and Cumulative Rates of Billed Diagnoses Along the Axis of Vaccination".
IPAK and Dr. Paul Thomas are now moving on to Phase 2 of our study, in which they will focus on the comparison of health outcomes associated with live vs. non-live vaccines, aluminum-containing vaccines vs. non-aluminum containing vaccines, as well as studying the impact of individual vaccines on specific health outcome risks.
To find our more, visit
Abstract: We performed a retrospective analysis spanning ten years of pediatric practice focused on patients with variable vaccination born into a practice, presenting a unique opportunity to study the effects of variable vaccination on outcomes. The average total incidence of billed office visits per outcome related to the outcomes were compared across groups (Relative Incidence of Office Visit (RIOV)). RIOV is shown to be more powerful than odds ratio of diagnoses. Full cohort, cumulative incidence analyses, matched for days of care, and matched for family history analyses were conducted across quantiles of vaccine uptake.
Increased office visits related to many diagnoses were robust to days-of-care-matched analyses, family history, gender block, age block, and false discovery risk. Many outcomes had high RIOV odds ratios after matching for days-of-care (e.g., anemia (6.334), asthma (3.496), allergic rhinitis (6.479), and sinusitis (3.529), all significant under the Z-test). Developmental disorders were determined to be difficult to study due to extremely low prevalence in the practice, potentially attributable to high rates of vaccine cessation upon adverse events and family history of autoimmunity.
Remarkably, zero of the 561 unvaccinated patients in the study had attention deficit hyperactivity disorder (ADHD) compared to 0.063% of the (partially and fully) vaccinated. The implications of these results for the net public health effects of whole population vaccination and with respect for informed consent on human health are compelling. Our results give agency to calls for research conducted by individuals who are independent of any funding sources related to the vaccine industry.
While the low rates of developmental disorders prevented sufficiently powered hypothesis testing, it is notable that the overall rate of autism spectrum disorder (0.84%) in the cohort is half that of the US national rate (1.69%). The practice-wide rate of ADHD was roughly half of the national rate. The data indicate that unvaccinated children in the practice are not unhealthier than the vaccinated and indeed the overall results may indicate that the unvaccinated pediatric patients in this practice are healthier overall than the vaccinated.